Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135,182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.
Houston BL, Jayakar J, Wells RA, Lenis M, Zhang L, Zhu N, Leitch HA, Nevill TJ, Yee KWL, Leber B, Sabloff M, St-Hilaire E, Kumar R, Geddes M, Shamy A, Storring JM, Keating MM, Elemary M, Delage R, Mamedov A, Buckstein R. Houston BL, et al. Among authors: zhang l. Ann Hematol. 2017 Dec;96(12):2025-2029. doi: 10.1007/s00277-017-3137-0. Epub 2017 Oct 3. Ann Hematol. 2017. PMID: 28975386
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M. Buckstein R, et al. Among authors: zhang l. Clin Cancer Res. 2006 Sep 1;12(17):5190-8. doi: 10.1158/1078-0432.CCR-06-0474. Clin Cancer Res. 2006. PMID: 16951238 Clinical Trial.
Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, Zhang L, Buckstein R. Guirguis HR, et al. Among authors: zhang l. Br J Haematol. 2012 Oct;159(1):39-49. doi: 10.1111/j.1365-2141.2012.09247.x. Epub 2012 Jul 31. Br J Haematol. 2012. PMID: 22849793 Free article. Review.
Survival of patients with transformed lymphoma in the rituximab era.
Guirguis HR, Cheung MC, Piliotis E, Spaner D, Berinstein NL, Imrie K, Zhang L, Buckstein R. Guirguis HR, et al. Among authors: zhang l. Ann Hematol. 2014 Jun;93(6):1007-14. doi: 10.1007/s00277-013-1991-y. Epub 2014 Jan 11. Ann Hematol. 2014. PMID: 24414374
Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis.
Buckstein R, Kerbel R, Cheung M, Shaked Y, Chodirker L, Lee CR, Lenis M, Davidson C, Cussen MA, Reis M, Chesney A, Zhang L, Mamedov A, Wells RA. Buckstein R, et al. Among authors: zhang l. Leuk Res. 2014 Jul;38(7):756-63. doi: 10.1016/j.leukres.2014.03.022. Epub 2014 Apr 5. Leuk Res. 2014. PMID: 24819395 Free article. Clinical Trial.
Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab.
Berinstein NL, Bhella S, Pennell NM, Cheung MC, Imrie KR, Spaner DE, Milliken V, Zhang L, Hewitt K, Boudreau A, Reis MD, Chesney A, Good D, Ghorab Z, Hicks LK, Piliotis E, Buckstein R. Berinstein NL, et al. Among authors: zhang l. Ann Hematol. 2015 May;94(5):813-23. doi: 10.1007/s00277-014-2288-5. Epub 2015 Jan 8. Ann Hematol. 2015. PMID: 25567231 Clinical Trial.
135,182 results
You have reached the last available page of results. Please see the User Guide for more information.